AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study

AtaiBeckley Inc (NASDAQ:ATAI) is among the 13 best NASDAQ penny stocks to buy according to analysts. On February 26, AtaiBeckley Inc (NASDAQ:ATAI) reported topline results from a Phase 2a trial of its drug candidate EMP-01 (oral R-MDMA), which is aimed for treating social anxiety disorder. According to AtaiBeckley, the study met its primary objectives, with EMP-01 showing efficacy signals with a favorable safe profile. In the US alone, social anxiety disorder is estimated to affect 30 million adults.

The release of these study results come on the back of AtaiBeckley making a key executive appointment. On February 19, AtaiBeckley Inc (NASDAQ:ATAI) announced that it had appointed Michael Faerm as its chief financial officer. It said the appointment is effective March 9. As CFO, Faerm will lead AtaiBeckley’s financial operations, financial strategy, and capital market strategies.

AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study

The latest analyst action on AtaiBeckley came on January 13, where Cantor Fitzgerald analysts reiterated their Overweight rating on ATAI stock without assigning it a price target.  In reaffirming their bullish outlook for AtaiBeckley, Cantor Fitzgerald analysts pointed to the potential of the company’s BPL-003 compound, saying it has the potential to become a key player in tackling treatment-resistant depression. For this view, the analysts cited the compound’s compelling efficacy outcome in Phase 2a and Phase 2b studies.

Based in Berlin, Germany, AtaiBeckley Inc (NASDAQ:ATAI) is a clinical-stage drug developer with a deep focus on mental health. It has several potential drugs in various development stages. Its most advanced project is the BPL-003, which is aimed for treatment-resistant depression. The BPL-003 is in Phase 3 development stage. Its other projects include VLS-01 and EMP-01, which are both in Phase 2.

While we acknowledge the potential of ATAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ATAI and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Italian Stocks to Buy in 2026.

Disclosure: None.  Follow Insider Monkey on Google News.